Evogene (EVGN) Payables (2012 - 2026)

Evogene (EVGN) posted Payables of $463.0 for Q1 2026, down 27.54% sequentially from $639.0 in Q4 2025, and down 99.92% YoY from $592000.0 in Q1 2025.

Evogene (EVGN) Payables (2012 - 2026) Analysis & Trends

Evogene has reported Payables for 15 years, with the latest figure at $463.0 in Q1 2026.

Quarterly Payables fell 99.92% year-over-year to $463.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $463.0 (down 99.92% YoY) and the FY2025 annual result came in at $639.0, down 99.95% from the prior year.
Payables slipped to $463.0 in Q1 2026 per EVGN's latest filing, from $639.0 in the prior quarter.
Over five years, Payables peaked at $2.2 million in Q4 2023 and troughed at $463.0 in Q1 2026.
A 5-year average of $1.0 million and a median of $1.0 million in 2024 frame the typical range for Payables.
The sharpest annual moves came in 2023 and 2025: Payables surged 110.23% in 2023, then plunged 99.95% in 2025.
Over 5 years, Payables stood at $1.0 million in 2022, then soared by 110.23% to $2.2 million in 2023, then sank by 43.62% to $1.2 million in 2024, then slumped by 99.95% to $639.0 in 2025, then slipped by 27.54% to $463.0 in 2026.
According to Business Quant data, Payables over the past three periods registered $463.0, $639.0, and $457000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Payables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	429.50 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.16 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	1.52 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	167.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	470.30 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	108.02 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	622.65 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	428.93 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	35.57 Mn
10	Evogene	4.38 Mn	4.38 Mn	204,000.00	463.00

Download Data